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S U M M A R Y
Background: Group B Streptococcus (GBS) strains are classiﬁed by the polysaccharide capsule, which is
an important virulence factor and stimulator of antibody-associated immunity. As GBS infections in
neonates may be life-threatening, GBS screening and intrapartum antibiotic prophylaxis have been
implemented for prevention. In Korea, there are few reports on the GBS serotype distribution and
antibiotic resistance patterns because GBS screening and intrapartum prophylaxis are not done
routinely.
Methods: The serotype distribution and antibiotic resistance of GBS in infants in Korea with invasive
bacterial infections were examined for the 19-year period 1995–2013. Isolates obtained previously from
hospitals located in three different regions were analyzed for capsular serotype by PCR and sequencing
and for antimicrobial susceptibility.
Results: Among 56 isolates serotyped, the most common serotypes were III (44.6%) and V (28.6%),
followed by Ia (14.3%), Ib (10.7%), and VI (1.8%). No penicillin-resistant strains were detected, however
51.8% of the strains had resistance to erythromycin and 55.4% showed clindamycin resistance.
Resistance was highest (93.8%) to both erythromycin and clindamycin for serotype V; all 15 isolates
resistant to erythromycin were cMLSB phenotype and had a high level of resistance to both erythromycin
and clindamycin with MIC levels >256 mg/ml, and all but one were positive for ermB.
Conclusion: In this study in Korea, serotype V was identiﬁed in a relatively large proportion of GBS
isolates and this serotype showed a high level of resistance to erythromycin and clindamycin in a
statistically signiﬁcant majority. Continuous monitoring of changes in clinical disease and molecular
characteristics is important for the treatment and prevention of invasive GBS disease in infants.
 2015 The Authors. Published by Elsevier Ltd on behalf of International Society for Infectious Diseases.
This is an open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-
nc-nd/4.0/).
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Group B Streptococcus (GBS), also known as Streptococcus
agalactiae, is a major cause of invasive disease, with the highest risk
during the ﬁrst 3 months of life. Invasive GBS disease is classiﬁed
by the age at onset. Early-onset disease (EOD) usually occurs§ The data in this article were presented at IDWeek 2014, Philadelphia, USA,
October 10, 2014.
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license (http://creativecommons.org/licenses/by-nc-nd/4.0/).within the ﬁrst 6 days and is most commonly acquired from the
mother during or before delivery. Clinical disease in EOD presents
as shock, respiratory difﬁculty, pneumonia, and meningitis. Late-
onset disease (LOD) occurs at 7 days and maternal obstetric
complications are not risk factors. Person-to-person transmission
can frequently occur from health care professionals in the hospital, or
from visitors and family members in the community. LOD is an
important cause of bacteremia, meningitis, and osteoarticular disease.1
GBS strains are classiﬁed by the polysaccharide capsule, which
is an important virulence factor and stimulator of antibody-
associated immunity. GBS is classiﬁed into 10 serotypes: types Ia,
Ib, II, III, IV, V, VI, VII, VIII, and IX. Predominant serotypes causingciety for Infectious Diseases. This is an open access article under the CC BY-NC-ND
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onset.2–4
As GBS infections in neonates may be life-threatening,
programs including screening pregnant women for carriage of
GBS and intrapartum antibiotic prophylaxis have been imple-
mented in an attempt to prevent these infections.5,6 Many reports
have shown a reduction in vertical transmission of GBS and EOD in
neonates following the introduction of these programs.7 However
there is concern that the increased use of antibiotics in women
during labor may lead to increases in antibiotic resistance among
GBS isolates.7 Also, antibiotic susceptibility tests for resistance to
erythromycin and clindamycin are important in cases of penicillin-
allergic women who are at risk of anaphylaxis. In Korea, GBS
screening and intrapartum prophylaxis are not done routinely,
partly because cost-effectiveness has not been shown due to the
relative infrequency of GBS infection.
The clinical characteristics of invasive GBS disease in infants in
Korea are reported here. An analysis was performed of the serotype
distribution of GBS isolates together with the antibiotic resistance
patterns.
2. Methods
2.1. Study design
Infants admitted to three tertiary hospitals in Korea during the
years 1995–2013 were included: Seoul National University
Children’s Hospital (Seoul), Seoul National University Bundang
Hospital (Seongnam), and Chonbuk National University Hospital
(Jeonju). These hospitals are all distant from each other. Cases from
the period 1995–2000 were all from Seoul National University
Children’s Hospital. Cases from Chonbuk National University
Hospital were included starting in 2001 and cases from Seoul
National University Bundang Hospital were included starting from
2003.
A case was deﬁned as an infant from whom GBS was isolated
from a normally sterile site, including blood, cerebrospinal ﬂuid
(CSF), and joint aspirates, or a culture-negative infant aged younger
than 89 days with evidence of meningitis and a positive latex
agglutination test in CSF. Patient demographic information and
details of their underlying diseases, clinical diagnoses, and
outcomes were collected from the medical records.
GBS infection was classiﬁed according to the onset of disease as
follows: early-onset (EOD), characterized by the onset of infection
during the ﬁrst 6 days after birth; late-onset (LOD), characterized
by the onset of infection at 7–89 days after birth.
Clinical cases were categorized as bacteremia, meningitis,
pneumonia, or osteoarticular disease, based on laboratory
conﬁrmatory tests and physician diagnoses recorded in the
medical records. Bacteremia was deﬁned as the growth of GBS
from blood culture without a focus, but with symptoms consistent
with bacteremia. Meningitis was deﬁned as the presence of clinical
symptoms with positive results on CSF culture, or culture-negative
cases with evidence of meningitis and a positive latex agglutina-
tion test in CSF. Pneumonia was deﬁned as the presence of clinical
symptoms with radiological ﬁndings and positive results on blood
culture. Osteoarticular disease was deﬁned as the presence of
clinical symptoms and positive results for joint aspiration and
tissue culture.
Outcomes were categorized as full recovery, death, or sequelae
with neurological complications (e.g., hydrocephalus, seizures, and
hearing loss), pulmonary complications (e.g., need for home
ventilator), or orthopedic complications (e.g., limitations in
movement).
This study was approved by the institutional review boards of
Seoul National University Hospital, Seoul National UniversityBundang Hospital, and Chonbuk National University Hospital. The
need for informed consent was waived.
2.2. Bacterial strains and antimicrobial susceptibility tests
Isolates from invasive GBS cases were collected prospectively
through a hospital-wide surveillance system at Seoul National
University Children’s Hospital (1995–2013) and Seoul National
University Bundang Hospital (2003–2013) and stored at 70 8C.
Isolates from Chonbuk National University Children’s Hospital
were provided by the Chonbuk National University Hospital
Culture Collection for Pathogens (2001–2013). The identiﬁcation of
GBS isolates was performed using automated microbiology
systems, including Vitek-1 (bioMe´rieux, Marcy l’Etoile, France)
and MicroScan Walk-Away (Siemens Healthcare Diagnostics,
Deerﬁeld, IL, USA). Isolates were subcultured on 5% sheep blood
agar plates and were identiﬁed in isolates that were Gram-positive,
showed b-hemolysis on sheep blood agar, and were CAMP test-
positive.7 Minimum inhibitory concentrations (MICs) were deter-
mined for penicillin, erythromycin, and clindamycin by gradient
diffusion Etest. The double disk synergy test (D-test) for
erythromycin and clindamycin was performed to determine the
inducible resistance. Isolates were regarded as susceptible,
intermediate, or resistant according to the interpretative criteria
published in the 2014 Clinical and Laboratory Standards Institute
guidelines (CLSI, 2014). For penicillin, a MIC 0.12 mg/ml was used
to deﬁne susceptibility. For both erythromycin and clindamycin, a
MIC 0.25 mg/ml indicated susceptibility and a MIC 1 mg/ml
indicated resistance. Macrolide resistance phenotypes obtained
from MICs were classiﬁed as cMLSB (constitutive macrolide,
lincosamide, and streptogramin B) for those with erythromycin
and clindamycin resistance, as iMLSB (inducible) for isolates with
erythromycin resistance that were clindamycin susceptible and D-
test-positive, and as M phenotype for isolates resistant to
erythromycin, sensitive to clindamycin, and D-test-negative. All
macrolide-resistant isolates were screened for causative molecular
resistance mechanisms. The ermA, ermB, and mefA genes were
detected using PCR ampliﬁcation, with primers as described
previously.8,9
2.3. Serotyping
The capsular polysaccharide types were determined by PCR
ampliﬁcation and sequencing of CPS type-speciﬁc regions of the
cps locus with serotypes Ia, Ib, and II through VII.10
2.4. Statistical analyses
Differences between categorical variables were tested using the
Chi-square test or Fisher’s exact test. All data were analyzed using
IBM SPSS Statistics for Windows, version 22.0 (IBM Corp., Armonk,
NY, USA), and the results were considered statistically signiﬁcant
when the p-value was less than 0.05.
3. Results
3.1. Clinical manifestations of invasive GBS disease
A total of 86 cases of invasive GBS disease were included in this
study; 42 cases occurred in males (48.8%). Twenty cases (23.3%)
were EOD and 66 (76.7%) were LOD (Table 1). Among EOD cases, 11
(55.0%) occurred within 3 days of birth; among LOD cases, 42
(63.6%) were diagnosed within the ﬁrst 7–30 days of life. Sixty-six
(76.7%) cases were born by vaginal delivery and 20 (23.3%) cases
were born preterm. There was no statistical difference in the type
of delivery or rate of preterm delivery between EOD and LOD cases.
Table 1
Clinical disease according to the age at onset
Clinical diagnosis Number of cases in each
diagnostic group (%)
p-Value
EOD (n = 20) LOD (n = 66)
Meningitis (n = 44) 7 (35.0) 37 (56.1) 0.13
Bacteremia (n = 35) 8 (40.0) 27 (40.9) 0.58
Pneumonia (n = 3) 3 (15.0) 0 (0) 0.01
Osteoarticular disease (n = 4) 2 (10.0) 2 (3.0) 0.22
EOD, early-onset disease; LOD, late-onset disease.
Table 3
Serotype distribution of invasive GBS isolates according to disease
Serotype Number of strains in serotype (%) p-Value
Meningitis
(n = 25)
Bacteremia
(n = 24)
Pneumonia
(n = 3)
Osteoarticular disease
(n = 4)
Ia 4 (16.0) 2 (8.3) 0 (0.0) 2 (50.0) 0.12
Ib 3 (12.0) 3 (12.5) 0 (0.0) 0 (0.0) 0.81
III 13 (52.0) 10 (41.7) 1 (33.3) 1 (25.0) 0.64
V 5 (20.0) 8 (33.3) 2 (66.7) 1 (25.0) 0.34
VI 0 (0.0) 1 (4.2) 0 (0.0) 0 (0.0) 0.74
GBS, group B Streptococcus.
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followed by bacteremia (n = 35; 40.7%); there were three (3.5%)
cases of pneumonia and four (4.7%) cases of osteoarticular
infection. The overall mortality was 5.8%, with no statistically
signiﬁcant difference between EOD and LOD cases (4.5% and 6.1%,
respectively). Among cases with invasive GBS disease, 73.3%
recovered fully and 20.9% had sequelae, all of which were due to
meningitis, such as hydrocephalus (n = 8), subdural empyema
(n = 2), subdural effusion (n = 2), intractable seizure (n = 3), and
intracranial hemorrhage (n = 2).
3.2. Serotype analysis
Among the 86 infant cases with a diagnosis of invasive GBS
infection, 56 were included in the serotype analysis. Reasons for
the exclusion of the 30 cases from the serotype analysis were the
following: 16 isolates were not retrievable, ﬁve cases were culture-
negative but diagnosed by a positive latex agglutination test in CSF
specimens, and nine cases were transferred from other hospitals
where the patients had been treated with antibiotics but had GBS
isolated before this treatment. Thirty-one of the isolates were from
Seoul National University Children’s Hospital, 10 were from Seoul
National University Bundang Hospital, and 15 were from Chonbuk
National University Hospital. Among the total 56 isolates included
in the serotype analysis, 14 (25.0%) were from EOD cases and 42
(75.0%) were from LOD cases. The serotype distribution is shown in
Table 2.
Among all serotypes in EOD and LOD, the most common was III
(44.6%), followed by V (28.6%), Ia (14.3%), Ib (10.7%), and VI (1.8%).
Overall, III, V, Ia, and Ib accounted for 98.2% of all cases.
Among EOD cases, serotype III was the most common (35.7%),
followed by V and Ia (both 21.4%), Ib (14.3%), and VI (7.2%). The
serotype distribution in LOD cases was similar to that in EOD cases:
serotype III (47.6%), followed by V (31.0%), Ia (11.9%), and Ib (9.5%).
The serotype distribution according to disease is shown in
Table 3. In meningitis cases, serotype III was predominant (52.0%),
followed by V (20.0%), Ia (16.0%), and Ib (12.0%). In bacteremia,
serotype III was predominant (41.7%), followed by V (33.3%), Ib
(12.5%), Ia (8.3%), and VI (4.2%).
In the ﬁrst 10 years of the study period (1995–2004), the
predominant serotypes were III and V, both accounting for 30.0%,
followed by Ib (20.0%), Ia (15.0%), and VI (5.0%). During the yearsTable 2
Serotype distribution of invasive GBS isolates according to the age at onset
Serotype Number of strains in serotype (%) p-Valuea
Total (n = 56) EOD (n = 14) LOD (n = 42)
Ia 8 (14.3) 3 (21.4) 5 (11.9) 0.39
Ib 6 (10.7) 2 (14.3) 4 (9.5) 0.47
III 25 (44.6) 5 (35.7) 20 (47.6) 0.52
V 16 (28.6) 3 (21.4) 13 (31.0) 0.86
VI 1 (1.8) 1 (7.2) 0 (0) 0.24
GBS, group B Streptococcus; EOD, early-onset disease; LOD, late-onset disease
a EOD vs. LOD.2005–2013, serotype III was the most common serotype (52.7%),
followed by serotypes V (27.8%) and Ia (13.9%). There were no
remarkable changes in serotype distribution when the two periods
were compared, however during the later period (2005–2013), Ib
accounted for only 5.6% (Table 4).
3.3. Antimicrobial susceptibility and association between antibiotic
resistance and serotype
No penicillin-resistant strains were detected among the
56 isolates. Erythromycin resistance was found in 51.8% and
clindamycin resistance in 55.4%. When analyzed by 5-year
intervals, the erythromycin resistance rate was 44.4% in 1995–
1999, 54.5% in 2000–2004, 44.4% in 2005–2009, and 61.1% in
2010–2013. Clindamycin resistance rates were 33.3% in 1995–
1999, 63.6% in 2000–2004, 55.6% in 2005–2009, and 55.6% in
2010–2013. Among erythromycin-resistant isolates, 24 (82.8%)
were classiﬁed as the cMLSB phenotype, three (10.3%) as iMLSB, and
two (6.9%) as the M phenotype. A large proportion of erythromy-
cin-resistant and clindamycin-resistant strains showed high levels
of resistance with MICs of >256 mg/ml (62.1% and 71.0%,
respectively).
Among the 29 erythromycin-resistant strains, ermB was
detected in 24 (82.8%), ermA in three (10.3%), and mefA in one
(3.4%); one strain had ermB and mefA (Table 5). The rate of
antibiotic resistance to erythromycin and clindamycin differed
according to the serotype. Among serotype V strains, erythromycin
and clindamycin resistance rates were both 93.8%. In serotype V, all
15 isolates resistant to erythromycin were cMLSB phenotype.
Moreover, all but one isolate had a high level of resistance to both
erythromycin and clindamycin, with MIC levels >256 mg/ml, and
were positive for ermB.
For serotype III, resistance rates to erythromycin and clinda-
mycin were 40%. Among the 10 erythromycin-resistant strains,
seven isolates had a MIC of 1–8 mg/ml, two had MICs >256 mg/ml,
and one had a MIC of 0.75 mg/ml. Among the 10 isolates resistant
to clindamycin, four had MICs >256 mg/ml.
Resistance to erythromycin and clindamycin for serotype Ib
was 43% and 50%, respectively, and for serotype Ia was 12.5% and
38%, respectively.Table 4
Changes in serotype distribution in invasive GBS disease, 1995–2013
Serotype Number of strains in serotype (%) p-Value
1995–2004
(n = 20)
2005–2013
(n = 36)
Ia 3(15.0) 5 (13.9) 0.56
Ib 4 (20.0) 2 (5.6) 0.09
III 6 (30.0) 19 (52.7) 0.12
V 6 (30.0) 10 (27.8) 0.50
VI 1 (5.0) 0 (0) 0.35
GBS, group B Streptococcus.
Table 5
Erythromycin resistance phenotype and genotype among isolates in invasive GBS disease, 1995–2013
Erythromycin resistance Number of isolates (%) with erythromycin resistance
Total (%) Ia
(n = 8)
Ib
(n = 6)
IIIa
(n = 25)
Va
(n = 16)
VI
(n = 1)
Overall 29 (51.8) 1 (12.5) 3 (50.0) 10 (40.0) 15 (93.8) 0 (0.0)
Genotype ermB 24 (82.8) 1b 3 5 14 0
ermA 3 (10.3) 0 0 3 0 0
mefA 1 (3.4) 0 0 1 0 0
GBS, group B Streptococcus.
a One isolate each of erythromycin-resistant serotypes III and V did not have ermB, ermA, or mefA.
b One isolate of serotype Ia had both ermB and mefA.
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to erythromycin (93.8%) and clindamycin (93.8%) than serotypes
Ia, Ib, and III (p < 0.05).
4. Discussion
In this study, the presence of differences in serotype of invasive
GBS disease in infants was determined. For the ﬁrst time in Korea,
the pattern of a marked predominance of serotype V with a high
level of erythromycin and clindamycin resistance among invasive
GBS disease in infants was demonstrated. Additionally, it was
conﬁrmed that, unlike in other countries, LOD (76.7%) was
signiﬁcantly more common than EOD (23.3%) in Korea, where
the low rate of EOD has not encouraged the development of a
screening program for this pathological entity.
Data on the prevalence of GBS infection in Korea are not
available. However, in a retrospective multicenter study including
18 institutions during the years 1996–2005, GBS (48.1%) was the
most common organism involved in invasive bacterial infection in
Korean children under 3 months of age and the most common
pathogen in bacterial meningitis in the same age group
(47.6%).11,12
Among the 157 invasive GBS cases in infants <3 months of age
(17 cases in this study were included, 12 from Seoul National
University Children’s Hospital and ﬁve from Chonbuk National
University Hospital), 32 (23.4%) were EOD and 125 (79.6%) were LOD,
and there was a trend towards an increase in LOD disease, although
there was no signiﬁcant change in EOD.13 This could be due to the
relatively low colonization rate in pregnant women in Korea; the
highest reported rate has been 11.5%, with others reporting rates
between 5.9% and 10.0%.14–16 However, EOD cases could be under-
estimated due to the lack of recognition of the pathogens in cases with
a rapid fatal course. Also, although routine screening for GBS during
pregnancy is not done, many women may take antibiotics before
delivery for other reasons, such as rupture of the membrane, clinical
signs of infection such as fever and discharge, etc.
In this study, the serotypes of invasive GBS disease were
analyzed and it was found that serotypes III (44.6%) and V (28.6%)
were the two most common, followed by Ia (14.3%), Ib (10.7%), and
VI (1.8%). This frequency is similar to that reported in a study done
in 2006–2008 among 2624 pregnant women in Korea, in whom the
carriage rate was determined to be 8%; serotypes III (43.8%) and V
(20.3%) were most common, followed by Ia (12.1%) and Ib (9.5%).16
A relatively high proportion of serotype V (28.6%) was found in
the present study, particularly in comparison with other countries
including Finland, Australia and New Zealand, England and Wales,
Denmark, and the USA (range 1–22%).17–21 According to a meta-
analysis including patients under 3 months of age from six World
Health Organization (WHO) regions for the period 1980–2011,
serotype V was the ﬁfth most common serotype (9.1%) after III, Ia,
Ib, and II.22 Since the late 1990s, there have been reports on theemergence and increase in serotype V, the change seen most
distinctly in colonizing strains and invasive disease among adults
in the USA and Sweden.23–25 To date, this study shows the highest
predominance of serotype V among infants with invasive disease.
Serotype V not only showed a high prevalence, but also showed
a high level of resistance (93.8%) to both erythromycin and
clindamycin. All erythromycin-resistant serotype V isolates
showed cMLSB resistance and all but one isolate had the ermB
gene. These ﬁndings are consistent with reports of colonizing
strains and other clinical isolates in Korea.26,27 The association of
serotype V and erythromycin resistance has also been described in
many countries.28,29 Serotype V has been reported to show very
close molecular relatedness within erythromycin-resistant strains,
showing evidence of genetic clustering of a macrolide-resistant
clone family. Studies based on molecular analysis have shown
evidence of clonal spread within each resistance mechanism group
and also multiclonal spread of resistant GBS clones.29,30 The high
proportion of serotype V in invasive infections in infants could be
due to the selective advantage of highly resistant strains.
Erythromycin and clindamycin resistance was not a problem
for serotype V only, but overall resistance was also seen in 51.8%
and 55.4%, respectively. Increases in erythromycin and clindamy-
cin resistance have been reported in other countries; a study
among pregnant and non-pregnant women in Italy showed an
increase from 16.5% in 2005 to 69.9% to 2008.31 However, in the
present study (for the period 1995–2013), erythromycin and
clindamycin resistance rates did not show a change over the years.
Given the high rates of resistance to erythromycin and clindamycin
in this study, prophylaxis or treatment with these antibiotics
should be considered after conﬁrmation of susceptibility. Data
from this study could serve as baseline data before GBS screening
and intrapartum antibiotic prophylaxis is introduced.
Another important strategy to prevent invasive GBS disease in
young infants is maternal vaccination. Vaccines are in development,
and when including serotypes Ia, Ib, and III, coverage with this
vaccine would be 69.6% based on the present data. The inclusion of
serotype V could increase coverage up to 98.2%. The inclusion of
serotype V could also have the additional beneﬁt of targeting strains
with high levels of resistance to erythromycin and clindamycin.
Considering the relatively high rate of serotype V demonstrated
in the present study, further studies on the changes in molecular
and clinical aspects of GBS infection are needed. Efforts directed at
the early detection and prevention of GBS infection should be
emphasized and local epidemiology data are essential for policies
aimed at prevention and treatment.
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